EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.314
https://www.valueinhealthjournal.com/article/S1098-3015(23)03444-7/fulltext
Title :
EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03444-7&doi=10.1016/j.jval.2023.09.314
First page :
Section Title :
Open access? :
No
Section Order :
12336